Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — Q2 2022 Earnings Presentation
18 slides from Bico Group Ab Class B's earnings presentation, Aug 24, 2022
Slide 1: Q2 Presentation / 24 August 2022 - Earnings Call
Q 2 PR E S E N TAT I O N / 2 4 AU G US T 2 02 2 - E A R N I N GS C A L L
Slide 2: Erik Gatenholm, President and CEO; Mikael Engblom, Interim Group CFO
ERIK GATENHOLM / PRESIDENT AND CEO MIKAEL ENGBLOM / INTERIM GROUP CFO 2 Q 2 P R E S E N TAT I O N 2 0 2 2
Slide 3: Agenda
AGENDA This is BICO BICO is creating the future of Q2 Highlights life-saving treatments by reducing the organ shortage and speeding up drug development Financial Performance Performace Update per Business Area Outlook 3 Q 2 P R E S E N TAT I O N 2 0 2 2
Slide 4: Q2 Highlights
Q2 Highlights 4 Q 2 P R E S E N TAT I O N 2 0 2 2
Slide 5: Q2 in summary
Q2 in summary 1 STRONG GLOBAL DEMAND AND CONTINUED HIGH SALES 2 FOCUS ON CUSTOMER CREDIT PROCESSES 3 FOCUS ON STRENGTHENING CASH FLOW 4 CONTINUED INTEGRATION AND INNOVATION 5 Q 2 P R E S E N TAT I O N 2 0 2 2
Slide 6: Financial Performance
Financial Performance Q2 6 Q 2 P R E S E N TAT I O N 2 0 2 2
Slide 7: Q2 April–June 2022 financial performance
APRIL – JUNE 2022 Q2 83 % 43.1 NET SALES TOTAL SALES GROWTH NET PROFIT/LOSS / MSEK / ROLLING 12 MONTHS /% / MSEK 1800 24 -62.9 73.0 % 1600 20 1400 1200 16 EBITDA GROSS MARGIN 1000 / MSEK /% 12 800 600 8 11.1 537.6 400 4 200 0 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q5 Q1 Q2 Q3 Q4 Q1 Q2 ADJUSTED EBITDA NET SALES
Slide 8: Half Year January–June 2022
JANUARY – JUNE 2022 Half Year 140 % -0.4 NET SALES TOTAL SALES GROWTH NET PROFIT/LOSS / MSEK / ROLLING 12 MONTHS /% / MSEK 1800 24 1600 -82.3 73.4 % 20 1400 1200 16 EBITDA GROSS MARGIN 1000 / MSEK /% 12 800 600 8 400 17.1 1,014.8 4 200 0 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q5 Q1 Q2 Q3 Q4 Q1 Q2 ADJUSTED EBITD
Slide 9: Focus on strengthening cash flow
Focus on strengthening APRIL – JUNE 2022 JANUARY – JUNE 2022 cash flow CASH FLOW FROM OPERATING ACTIVITIES Cash flow including changes in short-term investments during the second quarter amounted to SEK -323 million, reducing total cash reserves from SEK 1313 million per March 31 to SEK 991 million
Slide 10: Performance per Business Area
Performance per Business Area 10 Q 2 P R E S E N TAT I O N 2 0 2 2
Slide 11: Bioprinting
Bioprinting APRIL – JUNE 2022 JANUARY – JUNE 2022 47 % 46 % ORGANIC GROWTH ORGANIC GROWTH /% /% 153.7 276.7 NET SALES NET SALES / MSEK / MSEK BioNovaX, just launched this quarter by Allegro, which only joined the BICO family in May. The bioNovaX accelerates 7.4 8.9 research in biomimetic models, reg
Slide 12: Biosciences
Our newest acquisition, Biosero, continues to develop well, announcing a key patent underlying its Green But- ton Go® laboratory automation scheduling software. Biosciences Biosero also recently installed what may be the largest automated cancer diagnosis systems in the world. This system runs tests
Slide 13: Bioautomation
Bioautomation Providing relevant innovations under well-established brands to our target customers in diagnostics and pharma is a key driver for profitable growth. APRIL – JUNE 2022 JANUARY – JUNE 2022 One great example of this is how we strengthen our single cell proteomics offerings through a grea
Slide 14: Outlook
Outlook 14 Q 2 P R E S E N TAT I O N 2 0 2 2
Slide 15: Outlook
Outlook 1 ANTICIPATED MARKET SLOWDOWN 2 STRONG PRODUCT PORTFOLIO AND PIPELINE 3 FOCUS ON STRENGTHENING CASH FLOW 4 COMMITTED TO OUR STRATEGY 15 Q 2 P R E S E N TAT I O N 2 0 2 2
Slide 16: Upcoming Events; Bioconvergence is Enabling the Future of Health
Upcoming Events 9 NOVEMBER 2022 Interim report Q3 January–September 2022 Bioconvergence is 10 NOVEMBER 2022 Enabling the Future of Health Capital Markets Day Stockholm Bioconvergence is an emerging industry segment within healthcare and life sciences that emphasizes the convergence between multidisc
Slide 17: Disclaimer
DISCLAIMER You must read the following before continuing. The following applies to this document and the information provided in this presentation by BICO AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in connection with such pr
Slide 18: Join the Convergence Revolution
JOIN THE Bro CONVERGENCE REVOLUTION >>